397030 — AprilBio Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapNeutral

Annual income statement for AprilBio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0	23,396	200	0	27,514
Cost of Revenue
Gross Profit	0	23,396	—	—	—
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	9,188	18,950	11,664	13,385	10,768
Operating Profit	-9,188	4,446	-11,464	-13,385	16,746
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-10,344	-52,713	-8,959	-14,130	20,005
Provision for Income Taxes
Net Income After Taxes	-10,220	-52,713	-8,959	-14,130	20,005
Net Income Before Extraordinary Items
Net Income	-10,220	-52,713	-8,959	-14,130	20,005
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-10,220	-52,713	-8,959	-14,130	20,005
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-486	-2,507	-458	-661	919
Dividends per Share